Company profile
Ligand Pharmaceuticals Incorporated
NASDAQ: LGND · Healthcare · Biotechnology
PublicHQ Jupiter, CACIK 0000886163Reports USD
#260 of 1,420 Healthcare companies by revenuetop-quartile growth
EA Score
80B+FH 88DQ 78GM 60SS 80
v0.1 · 65/100 weight · provisional
↑ net margin, listing tenure · ↓ growth stability, workforce scale
Methodology →Revenue TTM
$274.5M
Rev growth YoY (TTM)
+51.2%
Net income (FY)
$124.5M
Employees
47
as of 2026-08-06
Market cap
$6.1B
as of 2026-08-06
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$268.1M$268.1M2025
Net income$124.5M$124.5M2025
Operating income$41.0M$41.0M2025
Total assets$1.6B$1.6B2025
Liabilities$543.4M$543.4M2025
Equity$1.0B$1.0B2025
Revenue trend
FY2021 – FY2025 · USD
FY21
FY22
FY22
FY22
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Royalty33%
Intangible Royalty Assets27%
Contract Revenue14%
Material Sales, Captisol, Core8%
Royalty, Kyprolis7%
Financial Royalty Assets6%
By geography
Not disclosed.
The read
What is Ligand Pharmaceuticals Incorporated’s revenue?
Ligand Pharmaceuticals Incorporated booked $268.1M in FY2025 revenue, growing 60% year over year — faster than most Healthcare companies we track, at a 46.4% net margin.
Peers · Healthcare
Harrow Health, Inc.73BViemed Healthcare, Inc.75B+Vireo Growth Inc.59CCareRx Corporation71BIovance Biotherapeutics, Inc.59CJushi Holdings Inc.54DKey facts
CEOTodd C. Davis
SectorHealthcare
IndustryBiotechnology
HeadquartersJupiter, CA
ExchangeNASDAQ: LGND
Employees47
IPO date1992-11-18
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.